The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP

Mark P Hamilton1, Kimal I Rajapakshe2, David A Bader1

  • 1Department of Molecular and Cell Biology, Baylor College of Medicine Hospital, Houston, TX, USA.

Neoplasia (New York, N.Y.)
|June 14, 2016
PubMed

Insights

MicroRNA deregulation drives prostate cancer (PCa) progression. This study reveals how miRNA targeting adapts to cancer genome changes, balancing oncogenic pathways in PCa development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNA (miRNA) deregulation is implicated in prostate cancer (PCa) initiation and metastasis.
  • Understanding miRNA targeting and function across PCa stages is crucial for therapeutic development.

Purpose of the Study:

  • To comprehensively map miRNA targets and their functional changes in PCa cell lines representing different disease stages.
  • To analyze stage-specific and tissue-specific miRNA targeting of known PCa drivers and pathways.

Main Methods:

  • Utilized photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of Argonaute protein.
  • Analyzed miRNA targeting in a panel of PCa cell lines modeling various stages of progression.

Main Results:

  • Identified androgen receptor as the most frequently targeted PCa oncogene.
  • Found miR-148a targets the largest number of known PCa drivers.
  • Demonstrated that miRNA targeting adapts to oncogenic pathways and cancer genome alterations.

Conclusions:

  • MiRNA targeting globally adapts to evolving cancer genomes, maintaining homeostasis in PCa.
  • This study provides the first global characterization of miRNA changes and their response to tumorigenesis in PCa.